Correction to: Significance of targeting DNMT3A mutations in AML

The original version of this article contained an error in the following sentences: "AML targeting systems consist of internalized anti-CD33-antibody-fisetin conjugates that spontaneously form vesicular nanocarriers in an aqueous solution with anionic molecules such as siRNA or iBrutiniB-Cy3.5 and cationic free fisetin.The siRNA specifically targets the DNMT3A mutation and FLT3ITD mutation in AML, leading to reduced clonal growth of AML cell lines in vitro and inhibiting tumor growth in xenograft cell lines in vivo [153]."The correct text should be:"AML targeting systems consist of internalized anti-CD33antibody-protamine conjugates that spontaneously form vesicular nanocarriers in an aqueous solution with anionic molecules such as siRNA or ibrutinib-Cy3.5 and cationic free protamine.The siRNA specifically targets the DNMT3A mutation and FLT3ITD mutation in AML, leading to reduced Correction to: Annals of Hematology h t t p s : / / d o i .o r g / 1 0 . 1 0 0 7 / s 0 0 2 7 7 -0